Kimberly-Clark CEO Mike Hsu told CNBC’s Jim Cramer that his company plans to acquire the maker of Tylenol. Kenview Even if the painkiller is scrutinized by the Trump administration, it will create value for shareholders.
He also said Tylenol sales “had some impact, but less than we thought,” and that Health and Human Services Secretary Robert F. Kennedy Jr. and President Donald Trump had promoted baseless claims linking the use of acetaminophen, Tylenol’s active ingredient, during pregnancy to autism.
“I think the brand is very resilient,” Hsu said. “I’m not an expert on Tylenol because it’s still in the introductory stage, but I think consumers are responding well because it’s a very effective and safe painkiller.”
Kimberly-Clark, which produces consumer goods such as Kleenex and Huggies, and Kenvue, famous for brands such as Tylenol, Neutrogena, Listerine, and band-aids. presentation Monday acquisition. The deal values the company at $48.7 billion and will create one of the world’s largest consumer staples companies.
When this news broke, Kimberly-Clark stock prices plummeted 14.57%, while Kenvue stock prices soared more than 12%.
